Communiqués Abbott Laboratories Kazakhstan S.E.

Actions

ABT_KZ

US0028241000

Equipement, fournitures et distribution médicale

Cours en clôture Kazakhstan S.E. 05/10/2026			Varia. 5j.	Varia. 1 janv.
110,00 ^USD	0,00%		+4,76%	-23,61%

05/10	Abbott Laboratories obtient l’autorisation de la FDA pour les nouvelles fonctionnalités du système CardioMEMS HF	CI
05/10	Abbott Laboratories obtient l’autorisation de la FDA d’intégrer des fonctionnalités interactives à son moniteur cardiaque CardioMEMS	MT

Communiqués

05/10	Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition	PR
30/09	Abbott hosts conference call for third-quarter earnings	PR
30/09	Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio	PR
25/09	Abbott Laboratories : Landmark study in people with Type 2 diabetes using basal insulin shows continuous glucose monitoring, including Abbott’s Libre technology, associated with lower risk of death and cardiovascular complications	PU
23/09	Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health	PR
17/09	Abbott declares 411th consecutive quarterly dividend	PR
15/09	First Canadian Commercial Use of Abbott's Volt™ Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation Care	AQ
15/09	Abbott to pay $385M over infant formula contamination probe	AQ
14/09	Abbott agrees to settlement over closure of largest baby formula plant in the US	AQ
14/09	Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall	PR
31/08	Abbott Laboratories : Late-breaking data for Abbott’s TactiFlex™ Duo Ablation Catheter reveal positive outcomes for treating complex AFib cases	PU
31/08	Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula	PR
27/08	Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke	PR
25/08	Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes	PR
20/08	Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants	PR
17/08	Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare	PR
12/08	Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis	PR
11/08	Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI	PR
28/07	Abbott Laboratories : initiates clinical study to show outcomes for real-world use of TriClip™ in repairing leaky tricuspid heart valve	PU
17/07	Army integrating new handheld device to quickly assess brain injuries	AQ
16/07	Abbott Laboratories : ABT 2026 Q2 Exhibit 99.1 FINAL	PU
16/07	Abbott: Q2 Earnings Snapshot	AQ
16/07	Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance	PR
25/06	Court Considers Whether Growth Claims Were Tall Tales	AQ
25/06	Abbott hosts conference call for second-quarter earnings	PR